Chest Pain Labs and Next Steps: What Tests to Expect and When to Act

Why Chest Pain Requires a Systematic Workup

Chest pain is one of the most common reasons adults visit an emergency department, yet fewer than 10% of those visits result in a diagnosis of acute coronary syndrome (ACS) [1]. The challenge is separating the small percentage of life-threatening causes from the far more common benign ones. A structured approach using labs, imaging, and validated risk tools prevents both missed diagnoses and unnecessary admissions.

The American Heart Association (AHA) and American College of Cardiology (ACC) published updated chest pain evaluation guidelines in 2021, emphasizing that "the initial assessment should integrate clinical history, physical examination, 12-lead ECG, and troponin measurement to guide subsequent testing and disposition" [2]. This document replaced earlier fragmented guidance with a single pathway applicable across emergency, inpatient, and outpatient settings.

Approximately 50% to 70% of chest pain cases turn out to be non-cardiac in origin [3]. Gastroesophageal reflux, costochondritis, and panic disorder are frequent culprits. Still, the diagnostic process must first exclude dangerous conditions. Acute myocardial infarction, pulmonary embolism, aortic dissection, and tension pneumothorax all present with chest pain and all require time-sensitive intervention.

The First 10 Minutes: ECG and Initial Assessment

A 12-lead electrocardiogram should be performed and interpreted within 10 minutes of a patient presenting with chest pain, according to the 2021 AHA/ACC guidelines [2]. ST-segment elevation on an ECG triggers an immediate activation of the cardiac catheterization lab. That single finding can compress the entire diagnostic timeline from hours to minutes.

Without ST-elevation, the ECG still provides data. ST-segment depression, T-wave inversions, or new left bundle branch block all raise suspicion for ACS and prompt serial troponin draws. A completely normal ECG does not exclude a cardiac cause, but it does shift probabilities. In a 2019 analysis published in The Lancet, a normal ECG combined with undetectable hs-cTn at presentation had a negative predictive value of 99.4% for myocardial infarction [4].

The physical examination matters too. Reproducible chest wall tenderness suggests a musculoskeletal source. Unequal blood pressures between arms raise concern for aortic dissection. A friction rub points toward pericarditis. None of these findings replace lab testing, but they guide the clinician's pre-test probability and determine which labs get ordered first.

High-Sensitivity Troponin: The Anchor Test

High-sensitivity cardiac troponin (hs-cTn) has replaced conventional troponin assays in most U.S. and European hospitals. These newer assays detect nanogram-per-liter concentrations of troponin, a protein released when heart muscle cells are damaged. The result is earlier detection. Conventional assays required 6 to 12 hours after symptom onset to turn positive. High-sensitivity assays can identify myocardial injury within 1 to 3 hours [5].

The 2020 European Society of Cardiology (ESC) rapid rule-out protocol uses hs-cTn at 0 and 1 hour (or 0 and 2 hours depending on the assay) [6]. If both values are below the assay-specific threshold and the change between them (the "delta") is minimal, myocardial infarction can be ruled out with a sensitivity exceeding 99%. In the original validation cohort of 1,810 patients, this 0/1-hour algorithm classified 60% of patients as "rule-out" with a miss rate of 0.1% [6].

Dr. John Nagurney, an emergency physician at Massachusetts General Hospital, has noted: "High-sensitivity troponin lets us make safe decisions faster. We can confidently discharge low-risk patients within two to three hours instead of holding them overnight for serial draws" [7].

A single elevated troponin does not automatically mean a heart attack. Troponin rises occur in heart failure, myocarditis, sepsis, renal failure, and even strenuous exercise. The pattern matters. A rising or falling trend on serial measurements, combined with a clinical picture consistent with ischemia, is what defines a Type 1 myocardial infarction. A stable, mildly elevated troponin in a patient with chronic kidney disease may represent chronic myocardial injury rather than an acute event.

The HEART Score: Turning Data Into a Decision

Raw lab values alone do not determine whether a patient gets admitted or discharged. Risk stratification tools convert clinical findings, ECG data, and lab results into an actionable score. The HEART score is the most widely adopted tool for this purpose in emergency departments.

Five components make up the score. History (0 to 2 points based on how typical the chest pain is for ACS). ECG findings (0 to 2 points). Age (0 to 2 points, with patients 65 and older receiving the maximum). Risk factors such as hypertension, diabetes, smoking, obesity, and family history (0 to 2 points). Troponin level (0 to 2 points). Total scores range from 0 to 10.

In a multicenter randomized trial of 3,648 patients (the HEART-FUL study), patients with HEART scores of 0 to 3 had a 30-day rate of major adverse cardiac events (MACE) of just 1.7% [8]. These low-risk patients were safely discharged from the ED with outpatient follow-up. Patients scoring 4 to 6 were observed and received additional testing. Those scoring 7 or above were typically admitted for invasive evaluation.

The HEART score does not replace clinical judgment. It provides a framework that standardizes what is otherwise a subjective decision. In practice, a score of 0 to 3 with two undetectable hs-cTn values and a normal ECG produces a very low probability of a missed ACS diagnosis.

Beyond Troponin: Other Labs in the Chest Pain Workup

Troponin is the headline test, but a standard chest pain workup includes several other laboratory studies. Each targets a different diagnostic possibility.

Complete blood count (CBC). Anemia can cause chest pain by reducing oxygen delivery to the heart. A white blood cell count may point toward infection or inflammation if pericarditis or pneumonia is on the differential.

Basic metabolic panel (BMP). Electrolyte abnormalities, particularly potassium and magnesium, can trigger arrhythmias that present as chest discomfort. Creatinine and blood urea nitrogen (BUN) values help interpret troponin. Chronic kidney disease patients often have chronically elevated troponin levels unrelated to ACS [9].

D-dimer. When pulmonary embolism (PE) is suspected, D-dimer serves as a screening test. In patients with a low Wells score, a negative D-dimer (<500 ng/mL) effectively excludes PE, with a sensitivity of approximately 97% [10]. A positive D-dimer is nonspecific and requires CT pulmonary angiography (CTPA) for confirmation.

BNP or NT-proBNP. B-type natriuretic peptide is released by stretched ventricular walls. Levels above 100 pg/mL (BNP) or 300 pg/mL (NT-proBNP) support a diagnosis of heart failure as the cause of chest tightness and dyspnea [11]. These biomarkers help differentiate cardiac from pulmonary causes of breathing difficulty accompanied by chest discomfort.

Lipid panel and hemoglobin A1c. Not part of the acute workup, these are often drawn during a chest pain visit to assess underlying cardiovascular risk. An LDL cholesterol above 190 mg/dL or an A1c above 6.5% changes the long-term management plan regardless of the acute diagnosis.

Imaging: When Labs Are Not Enough

A normal ECG and two undetectable troponin values in a low-risk patient often mean no imaging is needed. But when clinical uncertainty remains, imaging fills the gap.

Chest X-ray is typically the first imaging study. It cannot diagnose coronary artery disease, but it can reveal pneumothorax, pleural effusion, widened mediastinum (suggestive of aortic dissection), or pneumonia. It takes minutes and costs little.

Coronary CT angiography (CCTA) has become a preferred non-invasive test for intermediate-risk chest pain patients. The PROMISE trial (N=10,003) compared CCTA to functional stress testing and found similar outcomes, but CCTA provided a definitive anatomic diagnosis more often [12]. The 2021 AHA/ACC guidelines give CCTA a Class 1 recommendation for intermediate-risk patients with acute chest pain and no known coronary artery disease [2]. Its negative predictive value exceeds 99%, meaning a normal CCTA essentially rules out obstructive coronary disease.

Stress testing (exercise or pharmacologic with nuclear imaging or echocardiography) remains useful when CCTA is unavailable or when the question is about functional significance. Can the patient exercise to an adequate workload without ECG changes or symptoms? If yes, the prognosis is favorable.

Echocardiography is ordered when heart failure, valvular disease, pericardial effusion, or wall motion abnormalities are suspected. It does not directly visualize coronary arteries but reveals the downstream consequences of blocked or narrowed vessels.

Non-Cardiac Causes: The Majority of Cases

More than half of all chest pain evaluations end with a non-cardiac diagnosis [3]. Recognizing these causes prevents unnecessary cardiac catheterizations and long-term anxiety.

Gastroesophageal reflux disease (GERD) is the most common non-cardiac cause of chest pain. Burning substernal discomfort, worse after meals or when lying flat, that improves with antacids points strongly toward GERD. A trial of proton pump inhibitor therapy is both diagnostic and therapeutic. An upper endoscopy may follow if symptoms persist [13].

Musculoskeletal pain accounts for roughly 20% to 50% of chest pain presentations in primary care, according to a systematic review in BMC Family Practice [14]. The pain is typically sharp, worsens with movement or palpation, and localizes to a specific area on the chest wall. Costochondritis (inflammation of the costochondral junctions) is the most frequent subtype. Treatment is NSAIDs and reassurance.

Anxiety and panic disorder can produce chest tightness, palpitations, shortness of breath, and a sense of impending doom that closely mimics a cardiac event. The diagnosis is one of exclusion. Once cardiac causes have been ruled out, screening with validated tools (PHQ-9, GAD-7) and referral for cognitive behavioral therapy or pharmacotherapy is appropriate [15].

Pulmonary causes include pneumonia, pleuritis, and asthma exacerbation. These usually present with cough, fever, or wheezing alongside chest discomfort. Chest X-ray and pulse oximetry guide the workup.

When to Go to the Emergency Department

Not all chest pain requires an ambulance. But certain features demand immediate evaluation. Call 911 or go directly to an ED if chest pain is accompanied by any of these: sudden onset with radiation to the jaw, neck, or left arm; shortness of breath at rest; diaphoresis (cold sweats); syncope or near-syncope; new heart palpitations with hemodynamic compromise.

The AHA advises that "anyone experiencing chest pain that is new, unexplained, or lasts more than a few minutes should call 9-1-1 rather than drive themselves to the hospital" [16]. The reason is practical. Emergency medical services can perform a 12-lead ECG in the field and transmit it to the receiving hospital, activating the cath lab before the patient arrives if ST-elevation is present.

Pain that has been stable for weeks, worsens only with specific movements, and is reproducible on palpation is less likely to be cardiac. These patients may be appropriate for an outpatient evaluation with their primary care physician or cardiologist rather than an ED visit. A same-day or next-day appointment is reasonable when risk factors are low and symptoms are not accelerating.

Outpatient Follow-Up and Long-Term Next Steps

After an ED evaluation rules out acute coronary syndrome, the work is not finished. Follow-up within 72 hours with a primary care provider or cardiologist is standard practice for patients discharged with chest pain of uncertain etiology.

Outpatient next steps often include stress testing or CCTA if not performed in the ED. Risk factor modification begins immediately. Statin therapy for patients with elevated LDL, antihypertensive titration, smoking cessation counseling, and diabetes management all reduce future event risk. The 2019 ACC/AHA primary prevention guidelines recommend a 10-year atherosclerotic cardiovascular disease (ASCVD) risk calculation for all adults aged 40 to 75 to guide statin initiation [17].

For patients with non-cardiac chest pain, targeted treatment of the underlying cause (PPI for GERD, physical therapy for musculoskeletal pain, SSRI or CBT for panic disorder) is the next step. A clear explanation of the diagnosis reduces return ED visits. A 2017 study in Annals of Emergency Medicine found that patients who received a specific non-cardiac diagnosis at discharge had 40% fewer return visits within 30 days compared to those discharged with "chest pain, unspecified" [18].

Dr. Harlan Krumholz, a cardiologist at Yale School of Medicine, has emphasized: "The discharge conversation is as important as the diagnostic workup. Patients need to leave understanding what was ruled out, what was found, and exactly what they should do next" [19].

Long-term cardiovascular risk reduction is the final step. Regular exercise (150 minutes per week of moderate-intensity activity), a Mediterranean or DASH dietary pattern, weight management, and adherence to prescribed medications form the foundation. For patients found to have subclinical coronary artery disease on CCTA, aspirin and high-intensity statin therapy may be initiated based on plaque burden and calcium scoring [17].